$299.00
& Free ShippingWegovy 25 mg Tablets
Once-daily oral formulation
Product description
Wegovy 25 mg is the highest-strength oral semaglutide tablet in the approved four-strength oral formulation. It is intended as the maintenance strength in the published dose-escalation schedule for eligible adults receiving prescription weight-management treatment.
Semaglutide works by activating GLP-1 receptors, which play an important role in appetite regulation, satiety and food intake. When combined with a reduced-calorie diet and increased physical activity, treatment may help eligible adults achieve and maintain weight loss.
The 25 mg strength follows the gradual dose-escalation stages of 1.5 mg, 4 mg and 9 mg. It is generally used as the maintenance dose when prescribed and tolerated.
The appropriate maintenance dose depends on individual circumstances, treatment response and tolerability. Patients should not independently increase their dosage or switch from injectable to oral semaglutide.
Australian patients: The 25 mg tablet is registered by the TGA. Registration should not be confused with immediate retail availability or PBS subsidy.
Important regulatory consideration: Prescription-only medicines have strict advertising restrictions in Australia under the Therapeutic Goods Act and TGA advertising requirements. Public-facing promotion of prescription-only Wegovy, including product-specific promotional descriptions, calls to purchase and testimonials, can be problematic. Keep these pages educational and non-promotional, and obtain Australian regulatory review before publishing commercial product listings.
Useful references:
Wegovy® 25mg (Semaglutide) Tablets
Reviews
There are no reviews yet.